Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity by Ma, Xiaowei et al.
© 2012 Ma et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 1313–1328
International Journal of Nanomedicine
Xiaowei Ma*
Huan Wang*
Shubin Jin
Yan Wu
Xing-Jie Liang
Laboratory of Nanomedicine and 
Nanosafety, Division of Nanomedicine 
and Nanobiology, National Center for 
Nanoscience and Technology, People’s 
Republic of China; and CAS Key 
Laboratory for Biomedical Effects  
of Nanomaterials and Nanosafety, 
Chinese Academy of Sciences, Beijing, 
People’s Republic of China
*These authors contributed equally to 
this work
Correspondence: Xing-Jie Liang 
CAS Key Laboratory for Biomedical 
Effects of Nanomaterials and Nanosafety, 
Chinese Academy of Sciences, Beijing 
100190, People’s Republic of China 
Email liangxj@nanoctr.cn  
 
Yan Wu 
CAS Key Laboratory for Biomedical 
Effects of Nanomaterials and Nanosafety, 
Chinese academy of Sciences, Beijing 
100190, People’s Republic of China 
Email wuy@nanotr.cn
Background: There is an urgent need to develop drug-loaded biocompatible nanoscale   packages 
with improved therapeutic efficacy for effective clinical treatment. To address this need, a novel 
poly (2-hydroxyethyl methacrylate)-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoetha-
nolamine [PHEMA-g-(PLA-DPPE)] copolymer was designed and synthesized to enable these 
nanoparticles to be pH responsive under pathological conditions.
Methods: The structural properties and thermal stability of the copolymer was measured and 
confirmed by Fourier transform infrare  d spectroscopy, nuclear magnetic resonance, and ther-
mogravimetric analysis. In order to evaluate its feasibility as a drug carrier, paclitaxel-loaded 
PHEMA-g-(PLA-DPPE) nanoparticles were prepared using the emulsion-solvent evaporation 
method.
Results: The PHEMA-g-(PLA-DPPE) nanoparticles could be efficiently loaded with paclitaxel 
and controlled to release the drug gradually and effectively. In vitro release experiments dem-
onstrated that drug release was faster at pH 5.0 than at pH 7.4. The anticancer activity of the 
PHEMA-g-(PLA-DPPE) nanoparticles was measured in breast cancer MCF-7 cells in vivo and 
in vitro. In comparison with the free drug, the paclitaxel-loaded PHEMA-g-(PLA-DPPE) 
nanoparticles could induce more significant tumor regression.
Conclusion: This study indicates that PHEMA-g-(PLA-DPPE) nanoparticles are prom-
ising carriers for hydrophobic drugs. This system can passively target cancer tissue and release 
drugs in a controllable manner, as determined by the pH value of the area in which the drug 
accumulates.
Keywords: poly (2-hydroxyethyl methacrylate), controlled release, biocompatibility, antitumor 
activity, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, nanoparticles
Introduction
Scientists have been extensively researching ways to develop biocompatible and 
biodegradable drug carriers that possess certain clinically useful characteristics. 
Desirable characteristics include small particle size, high loading capacity, extended 
circulation time, ability to accumulate at pathological sites in the body, and the 
capacity to carry poorly soluble pharmaceuticals.1 As nanotechnology develops, 
nanoparticles are becoming very attractive for drug delivery. Nanoparticles are able 
to reach tumors passively through the leaky vasculature surrounding the tumor tissue 
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via the enhanced permeation and retention effect.2 Their 
prolonged circulation time gives the transported drug a 
better chance of reaching and/or interacting with its target 
tissue. Amphiphilic copolymers have attracted significant 
attention as carriers in drug delivery systems because they 
can form polymeric micelles by self-assembling in aqueous 
media. Polymeric micelles are composed of a hydrophilic 
shell and a hydrophobic core. They can thus enhance the 
solubility of poorly soluble drugs and increase their 
  bioavailability. Further, they can circulate in the body or 
blood for a long time and accumulate to a greater extent in 
the target region. This allows for effective sustained release 
of the drug inside tumor tissue following accumulation of 
micelles in tumor tissue.3
Poly (2-hydroxyethyl methacrylate) (PHEMA) and its 
block copolymers have been widely used in the pharma-
ceutical industry because of their biocompatibility and 
environmental friendly characteristics. PHEMA can easily 
form hydrogels,4 which are materials with a large number 
of biomedical applications due to their hydrophilic proper-
ties. Such applications include contact lenses, artificial 
implants, drug delivery systems, and nerve repair.5–9 How-
ever, the mechanical properties of PHEMA hydrogels do 
not fit the requirements for many structural applications. 
Therefore, amphiphilic polymers consisting of PHEMA 
and biodegradable polyesters, ie, poly(L-lactide) 
(PLLA),10,11 poly(D,L-lactide),12–14 poly(glycolic acid), 
poly(ε-caprolactone),15,16 and polystyrene, have been syn-
thesized.17 These copolymers can be obtained through 
ring-opening polymerization, atom transfer radical polym-
erization,11,18,19 A 2B2 PCl/acrylate miktoarm polymers,20 or 
use of a protective group, eg, a trimethylsilyl moiety.21 The 
mechanical strength of the materials obtained is expected 
to be improved through synthesis of amphiphilic materials 
and combination of PHEMA hydrogels with hydrophobic 
components.
Poly(lactic acid) (PLA) is a biodegradable aliphatic 
polyester and it is one of the biocompatible polymers 
approved by the US Food and Drug Administration.22,23 It 
has high mechanical strength, and excellent shaping and 
molding properties. Thus, it is widely used in medical fields 
for, eg, sustained drug delivery systems, implants for ortho-
pedic devices, and absorbable fibers.24,25 However, the low 
hydrophilicity and high crystallinity of PLA results in poor 
soft tissue compatibility.26 Dipalmytoylphosphatidyletha-
nolamine (DPPE) is the main constituent of the inner mem-
branes of cells. Some laboratories have reported that 
polyethylene glycol-phosphatidylethanolamine (PEG-PE) 
polymers can form stable micelles in aqueous media.27–29 
Their characteristic size, stability, and longevity in the sys-
temic circulation make micelles containing a PE segment 
promising carriers for drug delivery to tumor tissue via the 
enhanced permeation and retention effect.27–29 Amphiphilic 
triblock copolymers could interact with the phospholipid 
monolayer membranes of dipalmitoylphosphatidylcholine 
(DPPC) and dimyristoylphosphatidylcholine (DMPC).30 
Introduction of the PE segment could increase the internal-
ization of drug-loaded micelles into lysosomes by tumor cells 
and therefore enhance cytotoxicity.29 However, PEG-PE 
copolymers are expensive. Another drawback of PEG-based 
copolymers is the absence of reactive groups on their molecu-
lar chains, which limits further modification or ligand 
coupling.
Solid tumors account for more than 85% of cancer 
  mortality. The commercial formulation of paclitaxel 
(Taxol®) is dissolved in a 50:50 v/v mixture of Cremophor 
EL and dehydrated alcohol, and is very effective in the 
treatment of a broad range of solid tumors. However, its use 
is greatly limited by its poor solubility. Further, the Cremo-
phor EL-based formulation of paclitaxel often has serious 
side effects in patients, including allergic reactions, 
  neurotoxicity, and nephrotoxicity.31 Due to these serious 
problems, a delivery system that improves the solubility of 
paclitaxel and decreases its toxicity needs to be developed. 
There have been many attempts to formulate paclitaxel into 
a delivery system that does not require Cremophor for 
  solubilization. A number of alternative submicronic col-
loidal systems have been developed, including liposomes, 
microspheres, and polymeric micelles.32 However, the avail-
able optimized paclitaxel-based delivery systems (eg, 
albumin-bound paclitaxel nanoparticle formulations) for 
clinical application are very limited.
In the present work, we successfully synthesized a PHE-
MA-g-(PLA-DPPE) copolymer using a three-step process. 
We did so in order to combine the advantages of PHEMA and 
DPPE to form an antitumor drug (paclitaxel) carrier. Further, 
the chemical structure and physicochemical properties of the 
copolymers were investigated. It was found that paclitaxel 
could be loaded and incorporated into polymeric PHEMA-g-
(PLA-DPPE) nanoparticles by an emulsion-solvent evapora-
tion technique. We also investigated the physicochemical 
properties of these paclitaxel-loaded polymeric nanoparticles, 
including their size, loading content, encapsulation efficiency, 
and paclitaxel release profile. The potential of these nanopar-
ticles as efficient paclitaxel carriers was also evaluated. The 
in vitro cytotoxic activity and in vivo antitumor efficiency of 
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the paclitaxel-loaded   PHEMA-g-(PLA-DPPE) nanoparticles 
were evaluated in human breast cancer-bearing nude mice 
models. The results were compared with the antitumor effi-
ciency of free paclitaxel in the same conditions.
Materials and methods
Experimental materials
PHEMA (molecular weight 20 kDa), 1, 2-dipalmitoyl- 
sn-glycero-3-phosphoethanolamine, and triethylamine were 
purchased from Sigma Chemical Co (St Louis, MO). DL-
Lactide (DLLA), 4-nitrophenyl chloroformate (pNP), and 
4-dimethylaminopyridine were obtained from Alfar Aesar 
(Ward Hill, MA). Paclitaxel was purchased from Beijing 
HuaFeng United Technology Co, Ltd (Beijing, China). 
Cremophor EL was purchased from Aladdin Chemistry Co, 
Ltd (Collierville, TN). Dulbecco’s Modified Eagle’s 
Medium and fetal bovine serum were obtained from 
Hyclone (Logan, UT). All solutions were prepared with 
Milli-Q water (18 MΩ cm−1) from a Millipore system 
  (Billerica, MA). All other chemical reagents were analytical 
grade and used as received.
Synthesis of PHEMA-g-(PLA-DPPE) 
copolymer
Synthesis of the PHEMA-g-(PLA-DPPE) copolymer was a 
three-step process that can be described as follows. The 
PHEMA-PLA was synthesized by a previous reported one-
step ring-opening polymerization method,33 with some 
changes. Briefly, 10 g of DLLA was added to 500 mg of 
PHEMA-dimethyl sulfoxide (DMSO) solution by stirring, 
and then 0.01 mol triethylamine was added dropwise. The 
solution was reacted at 86°C by magnetic stirring under a 
nitrogen atmosphere. After 12 hours, the reacted solution 
was added to iced water and the precipitate was collected 
and thoroughly washed with distilled water three times. 
Finally, the raw product obtained was extracted with toluene. 
The pure PHEMA-PLA copolymer was dried at 40°C for 
48 hours under vacuum.
Activation of PHEMA-PLA to PHEMA-PLA-pNP was 
performed as described by Wang et al,34 with some modi-
fications. Briefly, 1.1 g of PHEMA-PLA was dissolved in 
6 mL of chloroform by stirring, and then 0.5 g of pNP, 
40 mg of 4-dimethylaminopyridine (dissolved in 6 mL of 
chloroform), and 1 mL of pyridine were added to the solu-
tion. The reaction took place at 0°C for 6 hours and at room 
temperature for 12 hours by magnetic stirring. The resulting 
product was added to diethyl ether-petroleum ether (2:1, 
v/v), and the precipitate was collected and washed with the 
mixed ether three times. The pure product was dried under 
vacuum for 48 hours.
The PHEMA-g-(PLA-DPPE) copolymer was synthe-
sized as follows. A mixture of PHEMA-PLA-pNP and DPPE 
(containing a measured amount of triethylamine) with a feed 
weight ratio of 20:1–50:1 (PHEMA-PLA-pNP/DPPE) was 
suspended in 20 mL of chloroform with magnetic stirring 
at 25°C in the absence of light. After being stirred continu-
ously for 12 hours, the resulting product was added to diethyl 
ether-petroleum ether (1:1, v/v). The precipitate was col-
lected and washed with the mixed ether three times. The 
PHEMA-g-(PLA-DPPE) obtained was dried under vacuum 
for 48 hours.
Characterization of PHEMA-g-(PLA-
DPPE) copolymer
The chemical compositions of PHEMA and PHEMA copo-
lymers were recorded using Fourier transform infrared 
spectroscopy (Perkin-Elmer, Fremont, CA). PHEMA and 
its copolymers were mixed with KBr and then pressed into 
a disk for measurement. Nuclear magnetic resonance 
(NMR) was also used to confirm the structure of the copo-
lymers.  1H NMR,  13C NMR, and  31P NMR spectra were 
recorded on a Bruker Avance 400 NMR spectrophotometer 
(Billerica, MA), with DMSO-d6 as the solvent. The thermal 
stability of the samples were measured by thermogravimet-
ric analysis using Perkin-Elmer Instruments with a heating 
rate of 20°C per minute under a nitrogen atmosphere from 
25°C to 900°C. Molecular weight and polydispersity were 
detected using gel permeation chromatography (Waters 
2410, Milford, MA).
Construction and characterization 
of paclitaxel-loaded copolymer 
nanoparticles
An emulsion-solvent evaporation method was used to prepare 
the paclitaxel-loaded PHEMA-g-(PLA-DPPE) nanoparticles 
as previously described.35 Briefly, 10 mg of PHEMA-g-
(PLA-DPPE) (20:1) copolymer was dissolved in 1.5 mL of 
methylene chloride. Paclitaxel (1 mg/mL in methylene chlo-
ride) was added at mass ratios of copolymer:paclitaxel of 
100/1, 70/1, and 50/1. The mixture was poured into 10 mL 
of 0.5%–2.0% (w/v) polyvinyl alcohol solution, stirred for 
10 minutes at room temperature, and then sonicated (50 w) 
for 5 minutes. The solvent was rapidly eliminated by evapo-
ration. Finally, the nanoparticles were collected by centrifu-
gation at 12,000 rpm for 5 minutes at room temperature and 
washed three times with water.
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Loading content and encapsulation 
efficiency of paclitaxel-loaded 
nanoparticles
The drug-loading content and encapsulation efficiency of the 
nanoparticles were determined by high performance liquid 
chromatography (HPLC, water, 626/2478). Briefly, 6 mg of 
lyophilized nanoparticles were dissolved in 1 mL of ace-
tonitrile under vigorous vortexing, and the clear solution was 
obtained for HPLC analysis. The mobile phase of HPLC was 
composed of acetonitrile:water 80/20 (v/v). The flow rate 
was 1.0 mL/minute at 25°C, and the wavelength was set at 
227 nm. The paclitaxel-loading content and encapsulation 
efficiency of the nanoparticles were calculated as follows:
Paclitaxel-loading content = Amount of paclitaxel in 
  nanoparticles/Amount of nanoparticles after  
  lyophilization × 100%    (1)
Encapsulation efficiency = Amount of paclitaxel in  
  nanoparticles/Initial amount of paclitaxel in the  
  system × 100%    (2)
PHEMA-g-(PLA-DPPE) nanoparticle size 
and distribution
The particle size and size distribution was measured using a 
Zetasizer NanoZS analyzer (Malvern Instruments Ltd, 
Worcestershire, UK) using the dynamic light scattering 
technique. The nanoparticles were appropriately diluted with 
distilled water. Determinations were performed at 633 nm 
with a constant angle of 90 degrees at 25°C.
Morphology of PHEMA-g-(PLA-DPPE) 
nanoparticles
The morphology of the nanoparticles was observed by trans-
mission electron microscopy (TEM, Tecnai G2 20,   Eindhoven, 
The Netherlands). For the TEM experiments, a drop of the 
sample solution was allowed to settle on a copper grid and 
the sample was air-dried. The nanoparticles were examined 
using TEM by negative staining with uranyl acetate.
In vitro drug release
Drug release experiments were carried out in vitro as follows. 
A 12 mg sample of lyophilized paclitaxel-loaded PHEMA-g-
(PLA-DPPE) nanoparticles was dispersed in 5 mL of phos-
phate-buffered saline and then introduced into dialysis bags 
(molecular weight 3500 g/mol). The dialysis bags were placed 
into 35 mL of phosphate-buffered saline (pH 7.4 or pH 5.0), 
and the media was stirred at 100 rpm and 37°C in a water bath. 
A 1 mL sample was then taken out for analysis of paclitaxel 
concentration at specific time intervals. Thereafter, 1 mL of 
the media was replaced with fresh distilled water. The con-
centration of paclitaxel released was determined using HPLC 
(Agilent 1200 Infinity LC, Santa Clara, CA).
Cytotoxicity assay
The inhibitory effects of the paclitaxel-loaded nanoparticles 
on human breast cancer cells were measured. MCF-7 cells 
were seeded into 96-well culture plates at 5000 cells/well 
and cultured at 37°C in a humidified atmosphere with 5% 
CO2 for overnight to allow for cell attachment. The cells 
were then exposed to a series of concentrations of free pacli-
taxel (DMSO , 1%) and paclitaxel-loaded nanoparticles. 
The final concentration of paclitaxel was in the range of 
0.001–50 µg/mL. The cells were further incubated for 
48 hours and cytotoxicity was assessed using CCK-8 kits 
(Dojindo Molecular Technologies, Tokyo, Japan).
Inhibition efficacy in breast cancer 
xenografts by intraperitoneal delivery
Female nu/nu nude mice (initially weighing 18–20 g and 
purchased from Beijing Vital River Company, Beijing, 
China) were used to investigate antitumor efficacy in vivo. 
The animals were housed under standard conditions with 
free access to food and water. All animal experiments were 
performed in accordance with the principles of care and use 
of laboratory animals. Briefly, approximately 2 × 106 
MCF-7 cells were resuspended in 100 µL of physiological 
saline, and injected subcutaneously into the right flanks of 
the nude mice. When tumors reached 50–70 mm3 in volume, 
the mice were randomly divided into three treatment groups 
(four mice per group). At days 7, 14, 21, 28, and 35 following 
inoculation, the physiological saline, Taxol 10 mg/kg, and 
paclitaxel-loaded nanoparticles (administered at a paclitaxel-
equivalent dose of 10 mg/kg) were administered intraperi-
toneally to the mice in the three treatment groups. Tumor 
progression in the mice was then monitored every four days. 
Tumor volumes were calculated as length × width2/2 (mm3). 
The mice were sacrificed at the end of the experiment, and 
their tumors were immediately removed and weighed.
Results
Synthesis and characterization  
of copolymer
PHEMA and PLA are two well established polymer materials 
and have been widely used in the medical and health care fields. 
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DMSO is a good solvent for PHEMA at room   temperature. 
In this study, we first synthesized PHEMA-PLA, a poly 
(lactide)-poly (2-hydroxyethyl methacrylate) grafted copo-
lymer, via a one-step ring-open polymerization method 
(Schema 1A). The molecular weight and polydispersity index 
of the PHEMA-PLA (PHEMA to DLLA 1:20) were 38 kDa 
and 1.28, respectively (determined by gel permeation chro-
matography). The method used was different from other 
previously reported methods.11,12,14 In the present work, pNP 
was selected for activation of the PHEMA-PLA copolymer 
(Schema 1B) according to a previously reported method, with 
some changes.34 The content of 4-nitrophenyl carbonate 
moieties could be determined during the reaction course. The 
degree of 4-nitrophenyl carbonate substitution could be 
controlled by adjusting the amount of chloroformate added. 
Finally, PHEMA-g-(PLA-DPPE) was synthesized in the 
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Schema 1 Synthetic route for (A) PHEMA-PLA, (B) PHEMA-PLA-pNP, and (C) PHEMA-g-(PLA-DPPE). 
Abbreviations:  PHEMA,  poly  (2-hydroxyethyl  methacrylate;  PLA,  poly  (lactide)-1;  DPPE,  2-dipalmitoyl-sn-glycero-3-phosphoethanolamine;  pNP,  4-nitrophenyl 
chloroformate.
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presence of triethylamine. The polymerization route is shown 
in Schema 1C. The molecular weight and polydispersity of 
the PHEMA-g-(PLA-DPPE) (PHEMA-PLA-pNP to DPPE 
20:1) were 43 kDa and 1.34, respectively (determined by gel 
permeation chromatography). The final products of PHEMA-
g-(PLA-DPPE) had good solubility in CH2Cl2, CHCl3, ace-
tone, and DMSO. The chemical structure and physicochemical 
properties of PHEMA and their copolymers were confirmed 
by Fourier transform infrared spectroscopy, 1H NMR, 
13C NMR, 31P NMR, and thermogravimetric analysis (some 
detailed descriptions and figures are shown in the supple-
mentary section).
Figure 1 shows the Fourier transform infrared spectra for 
the PHEMA, PHEMA-PLA, PHEMA-PLA-pNP, and 
PHEMA-g-(PLA-DPPE) copolymers, respectively. In 
  Figure 1A, the absorption peak appearing at approximately 
1729 cm−1 corresponds to the carbonyl group of the branched 
PHEMA; the bands at 3428 cm−1 and 1162 cm−1 were attrib-
uted to the O–H and the C–O stretching vibration, respec-
tively. Compared with the Fourier transform infrared spectra 
of PHEMA, the absorption peak at 1729 cm−1 transferred to 
1765 cm−1 in the PHEMA-PLA (Figure 1B). These results 
reflect the different location of the carbonyl group in the 
polymers. The intensity of the peak at 3428 cm−1 was weaker 
and wider after grafting of PLA. These results indicate that 
some changes occurred after grafting PLA onto the –OH of 
PHEMA. In Figure 1B, absorption peaks at about 2996 cm−1 
and about 2943 cm−1 were attributed to –CH2 absorption. In 
Figure 1C, the peak appearing at about 1754 cm−1 was attrib-
uted to 4-nitrophenyl carbonate, and this peak was overlap-
ping with the carbonyl group absorption peak at 1765 cm−1. 
The peaks at approximately 1594 cm−1 and about 1333 cm−1 
corresponded to –NO2 stretching   vibration. In the PHEMA-
g-(PLA-DPPE) copolymer, the peak at about 2680 cm−1 was 
attributed to PO–H stretching vibration (Figure 1D). All these 
results demonstrate that the intended copolymer had been 
obtained.
Figure 2 shows the 1H NMR spectra of PHEMA, PHEMA-
PLA, and the PHEMA-g-(PLA-DPPE) copolymer,   respectively. 
Compared with PHEMA (Figure 2A), the 1H NMR spectra of 
the PHEM-PLA copolymer (Figure 2B) indicate that the signals 
at about 1.3 and 1.5 ppm are attributable to the methyl protons 
of the PLA moiety located in the terminal groups and repeat 
units. The signals at about 4.2 and 5.1 ppm were attributed to 
the methine (CH) protons of the PLA moiety located in the 
terminal groups and repeat units. All these results confirm that 
the PHEMA derivatives contained a PLA side chain.14,15 In the 
1H NMR spectra of the PHEMA-g-(PLA-DPPE) copolymer 
(Figure 2C), the signal at about 0.9 ppm was attributed to the 
terminal methyl proton of the DPPE moiety. Peaks at 
1.2–1.6 ppm were attributed to methyl protons of the DPPE 
moiety. The signal at about 8.2 ppm was assigned to the proton 
of –NH in the DPPE moiety. All other absorption peaks were 
attributed to protons of the DPPE moiety. Further, typical 31P 
NMR spectra of DPPE and the PHEMA-g-(PLA-DPPE) copo-
lymer were recorded and are shown in Figure 2D and E.   
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Compared with DPPE (Figure 2D), the 31P NMR spectra of the 
PHEMA-g-(PLA-DPPE) copolymer (Figure 2E) show a peak 
at about 1.48 ppm that is generally expected for  31P 
functionalities.36,37 The 31P NMR spectra confirm that phosphate 
groups were chemically bonded to the material.
Characterization of nanoparticles
In this study, PHEMA, PLA, and DPPE were used to form 
size-controllable  nanoparticles  with  potential  for 
  pharmaceutical application. Given that PE is the main 
  constituent of the inner membrane of the cell, introducing 
DPPE into the copolymer may help to enhance the biocom-
patibility of the nanoparticles. In addition, according to previ-
ous research, the PE-containing DPPE segment fused rapidly 
when the medium pH was lowered from 7.0 to 5.0, and drug 
release increased during fusion of the materials. Previously 
published reports have also shown that PE is a pH-sensitive 
lipid component and has been used to trigger and enhance 
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drug release by liposomes. The hydrophobic segment 
(or anthracene ring) of an antitumor drug can interact with 
DPPE phospholipids upon encapsulation in nanoparticles, 
such that the drug has a higher encapsulation efficiency and 
loading content in the nanoparticles when the materials 
contain DPPE.29,38,39
PHEMA was chosen for the hydrophilic phase because 
of its biocompatibility, hydrophilicity, softness, high water 
content, and permeability. Because the primary purpose 
of this study was to deliver hydrophobic paclitaxel, as 
shown schematically in Figure 3A, an emulsion-solvent 
evaporation method was chosen to prepare the paclitaxel-
loaded nanoparticles. In a previous study, we showed that 
increasing the amount of PLA led to a highly viscous 
copolymer solution, which resulted in an increased particle 
size (data not shown). As a result, we chose a fixed ratio 
(1:20) of PHEMA-DLLA for conjugation of DPPE onto 
PHEMA-PLA and 20:1 of PHEMA-PLA-pNP to DPPE 
for balancing the loading of drug and controlling the size 
of the resulting nanoparticles. The drug-loaded nanopar-
ticles were lyophilized for longer storage and could be 
subsequently redissolved in water or phosphate-buffered 
saline for further use.
TEM was used to examine the morphology of empty 
PHEMA-g-(PLA-DPPE) nanoparticles and paclitaxel-loaded 
PHEMA-g-(PLA-DPPE) nanoparticles. The TEM images 
demonstrated that the nanoparticles became dispersed as 
individual particles with a typical spherical shape. They were 
homogeneously distributed around a size of 120–225 nm, as 
shown in Figure 3B (a and c). Dynamic light scattering was 
used to determine the average hydrodynamic diameters of 
the resulting nanoparticles. The diameters were approxi-
mately 170 nm, as shown in Figure 3B (b) and 240 nm as 
shown in Figure 3B (d) for empty PHEMA-g-(PLA-DPPE) 
  nanoparticles and paclitaxel-loaded PHEMA-g-(PLA-DPPE) 
  nanoparticles in water, respectively. The diameter observed 
by TEM was smaller than that detected by the Zetasizer 
NanoZS analyzer. This is because the diameter obtained by 
dynamic light scattering reflects the hydrodynamic diameter 
of nanoparticles swelling in aqueous solution. However, the 
diameter observed by TEM is the diameter of the dried 
nanoparticle.
Formulation parameters and size, loading 
content, and encapsulation efficiency
Size distribution (polydispersity index), paclitaxel-loading 
content, and encapsulation efficiency play an important role 
in in vitro studies and in vivo applications of drug-loaded 
nanoparticles. The effects of formulation parameters on 
size, drug-loading content, and encapsulation efficiency in 
this study are shown in Table 1. Size and size distribution 
of the nanoparticles was determined by dynamic light 
  scattering. The results show the effect of the feed mass ratio 
of copolymer to paclitaxel on the size of the paclitaxel-
loaded nanoparticles, which gradually increased as the 
paclitaxel content increased. After loading with paclitaxel, 
the nanoparticle size increased. When the initial paclitaxel 
feed amounts were varied, the size and loading content changed. 
Specifically, the higher the feed amount of paclitaxel, the 
larger the size and higher the paclitaxel loading content that 
was obtained (Table 1). This result is expected, because 
incorporation of paclitaxel into the hydrophobic cores 
increased with nanoparticle volume. The size difference 
before and after drug loading suggests that hydrophobic 
drug-loading increased the size of the nanoparticles. The 
same results were also observed in previous studies using 
other types of drugs.40
Polyvinyl alcohol was used in the current study as an 
emulsifier. As can be seen from Table 1, the mean diameter 
and polydispersity index of the nanoparticles, encapsulation 
efficiency, and loading content were investigated at different 
copolymer-drug ratios and polyvinyl alcohol concentrations. 
The viscosity of the suspension was significantly increased 
at high polyvinyl alcohol concentrations, which decreased 
the loading content and encapsulation efficiency. In our 
experiment, at every copolymer-drug ratio, increased nano-
particle size, decreased encapsulation efficiency, and 
decreased loading content was observed with increasing 
polyvinyl alcohol concentrations. In addition, too much 
polyvinyl alcohol should not be taken into the nanoparticles 
because it could not be totally biodegraded in vivo and was 
difficult to remove. Therefore, 0.5% polyvinyl alcohol was 
used for preparing the nanoparticles. At a copolymer-drug 
ratio of 100:1, the nanoparticles had the smallest size and 
polydispersity index, indicating their uniform distribution in 
solution. Therefore, a copolymer-drug ratio of 100:1 and 
0.5% was chosen for further biological study, with relatively 
high encapsulation efficiency and a loading content of 53.9% 
and 0.60%, respectively.
Controlled in vitro drug release from 
nanoparticles
It has been demonstrated that controlled and continuous drug 
release is essential for successful use of pharmaceuticals.41 
Figure 4 shows the in vitro release profiles for paclitaxel 
from nanoparticles. In all the curves, a burst effect was 
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observed within the first 24 hours. This was followed by a 
slow continuous release over the next 12 days at both pH 7.4 
and pH 5.0. This sustained release could result from diffusion 
of paclitaxel into the polymer wall, diffusion of the drug 
through the polymer wall, and erosion of the polymer. Drug 
release from copolymer nanoparticles is a rather complicated 
process. It can be affected by many factors, including polymer 
degradation, molecular weight, crystallinity, and the binding 
affinity between polymer and drug. In this study, the drug 
release rate might have been determined mainly by diffusion 
of the drug through the polymer matrix. The initial burst 
release of paclitaxel from the nanoparticles may be attribut-
able to the diffusion of paclitaxel located in close proximity 
to the surface of the PHEMA-g-(PLA-DPPE) nanoparticles. 
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Figure  3  Schematic  illustration  of  paclitaxel  encapsulation  into  nanoparticles  with  the  PHEMA-g-(PLA-DPPE)  copolymer  by  emulsion/solvent  evaporation  (A)  and 
transmission electron microscopy and dynamic light scattering characterization of empty and paclitaxel-loaded nanoparticles made by the emulsion/solvent evaporation 
method (B). Transmission electron microscopic image (a) and dynamic light scattering histogram, (b) of empty nanoparticles; transmission electron microscopic image 
(c) and dynamic light scattering histogram (d) of paclitaxel-loaded nanoparticles. 
Abbreviations: PHEMA, poly (2-hydroxyethyl methacrylate; PLA, poly (lactide)-1; DPPE, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.
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The PHEMA-g-(PLA-DPPE) copolymer under optimal 
delivery conditions would facilitate drug diffusion from the 
nanoparticle cores. At pH 5.0 and pH 7.4, release of paclitaxel 
from the nanoparticles over 12 days was 86.90% and 37.8%, 
respectively. These observations demonstrated that at pH 
5.0, paclitaxel was released much faster from the nanopar-
ticles than it was at pH 7.4. Our results are in agreement with 
previously published reports indicating that PE is a pH-
sensitive lipid component.42 Furthermore, the slowly con-
trolled release of paclitaxel from the nanoparticles at pH 
7.4 indicates that the paclitaxel-loaded nanoparticles are 
stable during circulation in the blood. Incorporation of 
  paclitaxel in nanoparticles could reduce systemic toxicity 
due to slower release in neutral body fluid.
Nanoparticle cytotoxicity  
in vitro and in vivo
To investigate the biological safety of PHEMA-g-(PLA-
DPPE) nanoparticles further, a blood smear test was per-
formed to determine if these nanoparticles can induce 
hemolysis in mice. Red blood cell morphology was observed 
after treating the mice with blank PHEMA-g-(PLA-DPPE) 
nanoparticles or incubating normal mice blood with different 
concentrations of PHEMA-g-(PLA-DPPE) copolymers. As 
can be seen from Figure 4B, no alteration in erythrocyte 
morphology was found in any of the treatment groups, indi-
cating that the nanoparticles have favorable blood 
compatibility.
Our nanoparticle formulation was assessed for its activity 
in cell culture. To compare the cytotoxicity of encapsulated 
and free paclitaxel, effects on cellular proliferation were 
examined using MCF-7 cells (Figure 5A). After treatment 
with free paclitaxel and paclitaxel-loaded nanoparticles, the 
proliferation of MCF-7 cells was quantified. Importantly, 
cells retained high viability after 48 hours in the presence of 
the empty nanoparticles at different concentrations under the 
experimental conditions. These results demonstrated that this 
nanoparticle formulation was not inherently cytotoxic.
Both the free paclitaxel and paclitaxel-loaded nanopar-
ticles significantly reduced tumor cell numbers in a concen-
tration-dependent manner as compared with the controls. In 
fact, the cytotoxic activity of the paclitaxel-loaded nanopar-
ticles and free paclitaxel showed equivalent trends in vitro, 
with IC50 values of 0.061 µg/mL for the free drug and 
0.050 µg/mL for the polymeric paclitaxel-loaded nanopar-
ticles. These data, together with the in vitro drug release 
results, suggest enhanced antitumor efficacy by the nanopar-
ticle delivery route in vivo.
Paclitaxel-loaded nanoparticles were next evaluated for 
their antitumor activity. The tumor volume growth curve 
(Figure 5B) shows that both free paclitaxel and the paclitaxel-
loaded nanoparticles effectively inhibited MCF-7 tumor 
growth, while the tumor growth rate in mice receiving 
paclitaxel-loaded nanoparticle treatment was much lower than 
in mice receiving treatment with free paclitaxel.   Figure 5C 
shows statistical analysis of tumor weights from the different 
treatment groups after sacrificing the mice at the end of the 
experiment. The results show that, compared with free pacli-
taxel (inhibition rate 45.42%), the inhibition rate in the group 
treated with paclitaxel-loaded nanoparticles was significantly 
increased to 63.65% (P , 0.05).   Representative images of 
excised tumors from mice receiving different treatment are 
shown in Figure 5D.
Discussion
Circumventing the deficiencies of first-line anticancer agents 
has not only scientific importance but also clinical signifi-
cance. Solubility of the compound is important for the che-
motherapeutic agent to take effect. About half of the 
potentially valuable drug candidates identified by high 
throughput screening technology (including those with the 
highest activity) demonstrate poor solubility in water. For this 
reason, the drugs are not developed further, and do not enter 
a formulation development stage.2 Paclitaxel is one of the 
most effective chemotherapeutic drugs in treating a variety 
of cancers. However, chemotherapy with paclitaxel has been 
Table 1 Effects of formulation parameters on size, size distribution, 
loading  content  of  paclitaxel,  and  encapsulation  efficiency  of 
paclitaxel-loaded PHEMA-g-(PLA-DPPE) nanoparticles
Copolymer:drug 
 ratio
100:1 70:1 50:1
0.5%PVA
  Mean diameter (nm) 239.8 ± 2.1 249.2 ± 1.6 257.3 ± 3.1
  PDI 0.114 ± 0.006 0.133 ± 0.008 0.189 ± 0.011
  EE (%) 53.90 ± 1.4 57.30 ± 1.2 67.00 ± 2.3
  LC (%) 0.60 ± 0.15 0.98 ± 0.17 1.65 ± 0.13
1%PVA
  Mean diameter (nm) 250.0 ± 2.3 259.5 ± 3.1 269.0 ± 4.0
  PDI 0.106 ± 0.004 0.151 ± 0.012 0.243 ± 0.010
  EE (%) 48.00 ± 1.2 51.00 ± 1.7 63.00 ± 2.5
  LC (%) 0.52 ± 0.13 0.85 ± 0.12 1.34 ± 0.16
2%PVA
  Mean diameter (nm) 269.2 ± 3.4 295.6 ± 2.5 301.2 ± 2.2
  PDI 0.211 ± 0.013 0.224 ± 0.009 0.253 ± 0.120
  EE (%) 42.40 ± 2.1 50.60 ± 1.9 61.00 ± 2.4
  LC (%) 0.39 ± 0.11 0.67 ± 0.13 1.18 ± 0.12
Abbreviations: PHEMA, poly (2-hydroxyethyl methacrylate; PLA, poly (lactide)-1; 
DPPE, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.
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Figure 4 (A) Accumulative release profiles of paclitaxel and paclitaxel-loaded nanoparticles at different pH values (copolymer/drug 100:1, polyvinyl alcohol 0.5%). (B) Effects 
of PHEMA-g-(PLA-DPPE) nanoparticles on erythrocyte morphology. Control: erythrocyte morphology in normal mice blood (a); erythrocyte morphology in mice after 
receiving blank PHEMA-g-(PLA-DPPE) nanoparticle treatment via intraperitoneal injection (b); erythrocyte morphology of mice blood after incubating the blood with a final 
concentration of 5 mg/mL PHEMA-g-(PLA-DPPE) copolymers for 3 hours (c), erythrocyte morphology of mice blood after incubating the blood with a final concentration of 
15 mg/mL PHEMA-g-(PLA-DPPE) copolymer for 3 hours. 
Abbreviations: PHEMA, poly (2-hydroxyethyl methacrylate; PLA, poly (lactide)-1; DPPE, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.
limited due to its poor solubility. Further, the   solubilizing 
agent Cremophor EL may cause severe anaphylactic hyper-
sensitivity reactions, hyperlipidemia, abnormal   lipoprotein 
patterns, aggregation of erythrocytes, and peripheral neuropa-
thy in patients.43 Accordingly, biocompatible polymeric 
paclitaxel-loaded nanoparticles without Cremophor EL have 
been developed to overcome these obstacles. Biocompatible 
and biodegradable polymers are particularly attractive for 
application in drug delivery systems. Once introduced into 
the human body, they do not require removal or additional 
manipulation. The results of the cytotoxicity assay demon-
strate that the patterns of cell viability in the presence of 
paclitaxel-loaded nanoparticles and the free drug were similar. 
This suggests that paclitaxel entrapped in nanoparticles was 
as potent as free paclitaxel in the tested tumor cell line. 
  Further, the polymeric nanoparticles used in our study had 
superior biocompatibility and may be a favorable alternative 
to the formulation approach involving Cremophor EL, thus 
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allowing for reduction of toxicity. In chemotherapy, 
  maintenance of drug levels in the body is usually achieved 
by repeated administrations. Despite the effectiveness of these 
treatments, dose peaks at   administration times are unavoidably 
alternated with subtherapeutic drug levels. Therefore, the 
impossibility of controlling the drug level over a long period 
of time constitutes an important drawback. We have compared 
free paclitaxel and paclitaxel-loaded PHEMA-g-(PLA-DPPE) 
nanoparticles in MCF-7 cells and found them to have com-
parable cytotoxic efficacy. Therefore, in our experiment, the 
nanoparticles exert their effects by changing the pharmacoki-
netics of paclitaxel at the animal level rather than by changing 
drug efficacy at the cellular level. In the case of solid tumors 
with compromised and leaky vasculature, localized drug 
delivery can be achieved largely as a function of particle size, 
and is referred to as “passive targeting”. The PHEMA-g-
(PLA-DPPE) nanoparticles used in our experiment had a 
particle size of about 200 nm. It has been reported that nano-
particles with a size around 200 nm would readily accumulate 
and be retained in the tumor interstitium because of the 
enhanced permeability and retention effect, which is further 
facilitated by the lack of a draining lymphatic system in tumor 
tissues.44–46 The circulation half-life of drug in the blood can 
be improved by coating it with a neural or anionic shell.47 In 
this case, we speculate that the hydrophilic polymer PHEMA 
shields charges and hydrophobic residues, reducing protein 
opsonization in vivo and thereby helps the nanoparticle to 
escape the reticuloendothelial system. This allows for pro-
longed circulation of paclitaxel and an extended drug effect. 
After entering the circulation, passive targeting of drugs to 
tumor tissue is achieved by the negatively charged PHEMA-
g-(PLA-DPPE) nanoparticles (zeta potential −23.4 mV). 
Previous reports have confirmed that PEG-PE polymers could 
form stable micelles in aqueous media and had longevity in 
the systemic circulation.29 From the results of our animal 
experiments, paclitaxel-loaded PHEMA-g-(PLA-DPPE) 
nanoparticles had a good inhibitory effect on tumor 
tissue, which we speculate may be due to the long circulation 
time and biocompatibility of the DPPE segment. According 
to the enhanced permeation and retention concept, 
A
D
B
C
0.2
0.4
0.6
0.8
1.0
1.2
1.4
T
u
m
o
r
 
w
e
i
g
h
t
 
(
g
)
*P < 0.05
SalineT axol PTX-NP
1E-30 .01 0.1 11 0
0
20
40
60
80
100
Drug concentration (µg/mL) 
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
)  Paclitaxel-loaded NPs
 Free paclitaxel
 Blank NPs
51 01 52 02 53 03 54 0
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
T
u
m
o
r
 
v
o
l
u
m
e
 
(
m
m
3
)
   Saline
 Saline  Saline Taxol Taxol PTX-NPP TX-NP
 Paclitaxel-loaded NPs
 Taxol
Days after tumor cell injection
Figure 5 (A) Inhibition of cancer cell proliferation by free paclitaxel and paclitaxel-loaded PHEMA-PLA-DPPE nanoparticles. Inhibition of MCF-7 cell proliferation by free 
paclitaxel, paclitaxel-loaded nanoparticles, or empty nanoparticles after 48 hours of incubation at 37°C. The concentration of empty nanoparticles used was equal to the 
concentration of paclitaxel-loaded nanoparticles. Tumor volume (B) and tumor weight (C) of MCF-7 tumor-bearing female nude mice treated with saline, paclitaxel, or 
paclitaxel-loaded PHEMA-g-(PLA-DPPE) nanoparticles. Data are presented as the mean ± standard deviation (n = 4). (D) Representative images of excised tumors from mice 
treated with saline, free paclitaxel, or paclitaxel-loaded PHEMA-g-(PLA-DPPE) nanoparticles. 
Abbreviations: PHEMA, poly (2-hydroxyethyl methacrylate; PLA, poly (lactide)-1; DPPE, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.
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  biocompatible macromolecules accumulate at much higher 
concentrations in tumor tissues than in normal tissues or 
organs, and at even higher levels than in plasma. The mecha-
nism by which pH-responsive polymeric paclitaxel-loaded 
PHEMA-g-(PLA-DPPE) nanoparticles outperform the free 
drug may be due to controlled drug release, achieved by 
slowing drug leakage during circulation in the blood. Blood 
has a pH of 7.4, and accumulates and releases the drug after 
reaching tumor areas which have a more acidic pH. A slower 
release rate at pH 7.4 than at pH 5 gives the drug maximum 
protection during its circulation in the blood and other body 
fluids, and thereby maintains an effective therapeutic concen-
tration for a longer period of time and increases overall 
accumulation of the drug in the tumor tissue.
Conclusion
In the current study, we developed a novel amphiphilic 
PHEMA-g-(PLA-DPPE)-based nanocarrier for delivery of the 
hydrophobic drug, paclitaxel. The paclitaxel-loaded copolymer 
nanoparticles fabricated using the emulsion-solvent evapora-
tion method were shown to have the following properties: 
bioapplication and bioabsorbability of PHEMA derivatives; 
markedly improved solubility of paclitaxel and without use of 
Cremophor EL; high loading capacity; and a controlled drug 
release profile. Paclitaxel-loaded polymeric nanoparticles were 
as cytotoxic to MCF-7 cells as free paclitaxel, while no cyto-
toxicity was observed to the polymers themselves. In mice, 
paclitaxel-loaded nanoparticles showed enhanced antitumor 
efficacy compared with free paclitaxel. Based on these results, 
it is expected that this PHEMA-g-(PLA-DPPE)-based drug 
packaging nanocarrier technology would provide a new strat-
egy for delivery of hydrophobic antitumor therapeutics.
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Supplementary details on 
copolymer synthesis and 
characterization
Supplementary Figure S1A–C show the 13C NMR spectra 
for PHEMA, PHEMA-PLA, and PHEMA-g-(PLA-DPPE) 
copolymer,  respectively.  Compared  with  PHEMA 
  (Supplementary Figure S1A), the 13C NMR spectra of the 
PHEMA-PLA copolymer (Supplementary Figure S1B) show 
that the signals at about 160–175 ppm were attributed to the 
C=O group carbon peak of PLA. The signals at   approximately 
64 and 69 ppm were assigned to the –CH group carbon peak 
of the PLA moiety located at the terminal groups and repeat 
units in the chain. The signals at approximately 15 and 20 
ppm were attributed to the –CH3 group carbon peak of the 
PLA moiety located at repeat units and the terminal groups. 
Compared with PHEMA-PLA (Supplementary Figure S1B), 
PHEMA-g-(PLA-DPPE) (Supplementary Figure S1C) 
showed a peak at about 9.0 ppm. This was attributed to 
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Figure S1 13C NMR spectra of PHEMA (A), PHEMA-PLA (B), and PHEMA-g-(PLA-DPPE) copolymers (C). 
Abbreviations: PHEMA, poly (2-hydroxyethyl methacrylate; PLA, poly (lactide)-1; DPPE, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.
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Figure S2 Thermogravimetric analysis profiles of (A) PHEMA, (B) PHEMA-PLA, and (C) PHEMA-g-(PLA-DPPE) copolymers. 
Abbreviations: PHEMA, poly (2-hydroxyethyl methacrylate; PLA, poly (lactide)-1; DPPE, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.
the –CH3 group carbon peak of the DPPE moiety located at 
the terminal groups. The signals at about 15–20 ppm were 
assigned to the –CH2 group carbon peak of the DPPE moiety. 
The signals at about 170 ppm were assigned to the C=O 
group carbon peak of PHEMA-g-(PLA-DPPE). All other 
absorption peaks were attributed to the carbon peaks of the 
DPPE moiety.
The thermal properties of polymers were examined by 
thermogravimetric analysis. Figure S2 shows the thermogra-
vimetric analysis for PHEMA, PHEMA-PLA, and PHEMA-
g-(PLA-DPPE) copolymers, respectively. As shown in 
Figure S2, the PHEMA-PLA and the PHEMA-g-(PLA-DPPE) 
copolymers had a lower thermal degradation temperature 
than the original PHEMA. Rapid weight loss appeared 
in the thermogravimetric analysis curves for copolymers in 
the thermal degradation range above 150°C, and lower than 
PHEMA at 250°C. We can conclude that the introduction of 
PLA and DPPE into the copolymer led to a decrease in the 
thermal stability of the original PHEMA. 
Abbreviations
PHEMA, poly (2-hydroxyethyl methacrylate; NMR, nuclear 
magnetic resonance; PLA, poly (lactide)-1; DPPE, 
2-  dipalmitoyl-sn-glycero-3-phosphoethanolamine.
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